Increasing Access to Lung Cancer Screening Act

This bill, HR6178, mandates that State Medicaid plans cover annual lung cancer screenings for eligible individuals as recommended by the U.S. Preventive Services Task Force, without prior authorization or cost sharing. It also expands Medicaid coverage for tobacco cessation counseling and pharmacotherapy beyond pregnant women to all individuals. This legislation directly increases demand for lung cancer screening services and tobacco cessation products and services by removing financial barriers for a significant population segment. The bill amends sections 1905(a)(4), 1916, and 1916A(b)(3)(B) of the Social Security Act, ensuring these services are covered under Medicaid and Medicaid Managed Care Organizations. The money trail for lung cancer screenings flows to diagnostic imaging providers and clinical laboratories. Companies operating imaging centers, such as those providing CT scans, will see increased patient volume. Clinical laboratories performing related diagnostics will also benefit. For tobacco cessation, pharmaceutical companies manufacturing nicotine replacement therapies and other cessation drugs, as well as pharmacies dispensing these products, will experience increased demand. The bill mandates coverage under Medicaid, meaning federal and state funds will directly pay for these services, creating a stable, government-backed revenue stream. Historically, similar expansions of preventive care coverage under government programs have led to increased utilization and revenue for providers. For example, when the Affordable Care Act (ACA) expanded coverage for preventive services in 2010, diagnostic and laboratory service providers saw sustained growth. While specific market data for lung cancer screening expansion is limited, the general trend for mandated coverage of preventive services is a direct increase in patient volume. The bill's sponsors, including Rep. Castor, a Democrat, indicate a focus on health policy expansion, which aligns with historical Democratic legislative priorities in healthcare. Specific winners include large diagnostic laboratory companies like LabCorp ($LH) and Quest Diagnostics ($DGX), which will see increased demand for related blood tests and pathology services. Retail pharmacy chains such as Rite Aid, CVS Health ($CVS), and Walgreens Boots Alliance will benefit from increased dispensing of tobacco cessation pharmacotherapy. Healthcare distributors like McKesson ($MCK) and Cardinal Health ($CAH) will see increased sales of these pharmaceuticals to pharmacies and healthcare providers. Staffing companies like AMN Healthcare Services ($AMN) may see increased demand for radiology technicians and other healthcare professionals needed for screenings. There are no clear losers, as the bill expands services without imposing new costs or restrictions on existing market participants. This bill has been referred to the Committee on Energy and Commerce and the Committee on Ways and Means. The next step is committee consideration, which includes hearings and potential markups. Given the bipartisan sponsorship (Rep. Fitzpatrick is Republican) and the nature of expanding preventive health services, the bill has a reasonable chance of advancing. If it passes committee, it moves to a floor vote in the House. The timeline for passage is uncertain but could extend through the current legislative session.